[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Zülfikar B: Two patients with haemophilia and acute leukaemia. Haemophilia; 2002 Sep;8(5):698-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two patients with haemophilia and acute leukaemia.
  • Acute leukaemia is the commonest form of malignancy in childhood.
  • The coincidental development of leukaemia in children or adults with haemophilia is extremely rare, although cases of leukaemia and other malignancies have been reported previously in HIV-positive subjects.
  • Of a total of 440 people with haemophilia registered with our society, two were diagnosed with acute leukaemia last year.
  • The development of leukaemia in a subject with haemophilia has previously been reported from our country in 1985, but the negative HIV status of these recent cases is very interesting.
  • The first case involved a 14-year-old boy with moderate haemophilia A, who developed acute lymphoblastic leukaemia (ALL) [French-American-British (FAB) classification L2].
  • The second subject was a 16-year-old boy who had moderately severe haemophilia A with no previous family history, and developed acute nonlymphocytic (myelomonocytic) leukaemia (FAB-M4).
  • Both patients received conventional chemotherapy and this report discusses the potential problems in management of such cases, including diagnosis and administration of chemotherapy in subjects with a pre-existing haemorrhagic disorder.
  • Extensive cutaneous and mucosal bleeding, as well as bleeds in joints previously affected by haemarthrosis and alterations of haematological values were all initially suggestive of the development of inhibitors against factor VIII, but the appearance of blasts in the peripheral blood and bone marrow led to the definitive diagnosis.
  • The risk of bleeding, due to the combination of both leukaemia and the consequences of the chemotherapy, was overcome by the administration of coagulation factor concentrates (daily initially followed by prophylactic doses after successful induction of remission in both patients).
  • An important lesson to be learnt from these cases is that the possible diagnosis of leukaemia should not be overlooked in a patient with haemophilia and severe haemorrhagic problems, if the first-line differential diagnosis of inhibitor development against factor VIII (or IX) has been excluded.
  • [MeSH-major] Developing Countries. Hemophilia A / complications. Leukemia, Myelomonocytic, Acute / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Cost of Illness. Fatal Outcome. HIV Seronegativity. Humans. Immunosuppressive Agents / therapeutic use. Male. Turkey

  • MedlinePlus Health Information. consumer health - Hemophilia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12199682.001).
  • [ISSN] 1351-8216
  • [Journal-full-title] Haemophilia : the official journal of the World Federation of Hemophilia
  • [ISO-abbreviation] Haemophilia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


2. Sotomayor EM, Piantadosi S, Miller CB, Karp JE, Jones RJ, Rowley SD, Kaufmann SH, Braine H, Burke PJ, Gore SD: Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy. Leuk Res; 2002 May;26(5):461-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.
  • We report single institution outcome of brief, intensive ara-C-based chemotherapy using bone marrow transplantation as primary intensification for untreated adult patients with acute lymphoblastic leukemia (ALL).
  • Overall disease-free and overall survival were inferior to those reported with prolonged chemotherapy modeled on pediatric protocols.
  • Survival and disease-free survival were superior for patients receiving allogeneic BMT compared with chemopurged autologous transplant or maintenance chemotherapy (patients ineligible for or declining BMT).
  • In multivariate analysis, non-L2-FAB, higher ara-C dose, absence of CNS disease, non-Ph1+ karyotype, allogeneic BMT, T cell phenotype, and younger age were associated with improved disease-free survival.
  • Autologous BMT was not superior to chemotherapy, and appears unlikely to provide adequate curative treatment for most adult ALL patients if not followed by maintenance.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bone Marrow Transplantation. Cytarabine / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Follow-Up Studies. Humans. Middle Aged. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2002 May;26(5):473-6 [11916521.001]
  • (PMID = 11916520.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 06973; United States / NCI NIH HHS / CA / CA 15396
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


3. Yokoyama H, Mizutani R, Satow Y, Komatsu Y, Ohtsuka E, Nikaido O: Crystal structure of the 64M-2 antibody Fab fragment in complex with a DNA dT(6-4)T photoproduct formed by ultraviolet radiation. J Mol Biol; 2000 Jun 9;299(3):711-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystal structure of the 64M-2 antibody Fab fragment in complex with a DNA dT(6-4)T photoproduct formed by ultraviolet radiation.
  • The crystal structure of the Fab fragment of the murine 64M-2 antibody specific to DNA T(6-4)T photoproducts is determined as a complex with dT(6-4)T, a (6-4) pyrimidine-pyrimidone photodimer of dTpT, at 2.4 A resolution to a crystallographic R-factor of 0.199 and an R(free) value of 0.279.
  • The 64M-2 Fab molecule is in an extended arrangement with an elbow angle of 174 degrees, and its five complementarity-determining regions, except L2, are involved in the ligand binding.
  • The bound dT(6-4)T ligand adopting a ring structure with (6-4) linked 5' thymine-3' pyrimidone bases is fully accommodated in an antigen-binding pocket of about 15 Ax10 A.
  • Three water molecules are located at the interface between the bases and the Fab residues.
  • Hydrogen bonds involving these water molecules also contribute to Fab recognition of the dT(6-4)T bases.
  • [MeSH-major] Antibodies, Antinuclear / chemistry. DNA / chemistry. DNA / immunology. Immunoglobulin Fab Fragments / chemistry. Nucleic Acid Conformation / radiation effects. Ultraviolet Rays

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10835279.001).
  • [ISSN] 0022-2836
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / DNA, Single-Stranded; 0 / Epitopes; 0 / Immunoglobulin Fab Fragments; 0 / Immunoglobulin Variable Region; 0 / Nucleotides; 0 / Pyrimidine Dimers; 059QF0KO0R / Water; 9007-49-2 / DNA
  •  go-up   go-down


Advertisement
4. Lee S, Kim DW, Kim YJ, Park YH, Min CK, Lee JW, Min WS, Kim CC: Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission. Br J Haematol; 2002 Apr;117(1):109-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission.
  • The prognostic relevance of karyotype has been established in adult acute lymphoblastic leukaemia (ALL) patients treated with chemotherapy but not definitively evaluated in an allogeneic bone marrow transplantation (BMT) setting.
  • The distribution of French-American-British (FAB) subtypes was as follows: L1 (n = 26), L2 (n = 15).
  • Unfavourable karyotypes (n = 12) were defined as Ph+ or t(4;11).
  • Disease status at the time of transplant was first CR (n = 35) or second CR (n = 6).
  • Potential variables predicting worse relapse and DFS were FAB subtype (L2), extramedullary involvement, pre-BMT status (second CR), unfavourable karyotype and type of graft-versus-host disease (GVHD).
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Philadelphia Chromosome. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease. Humans. Male. Multivariate Analysis. Patient Selection. Prognosis. Recurrence. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11918540.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Zuo YX, Zhang LP, Lu AD, Wang B, Liu GL: [Clinical characteristics of children with B cell type acute lymphoblastic leukemia carrying different fusion gene]. Zhongguo Dang Dai Er Ke Za Zhi; 2010 Mar;12(3):172-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of children with B cell type acute lymphoblastic leukemia carrying different fusion gene].
  • OBJECTIVE: To investigate whether there were differences in the clinical characteristics, cytogenetic characteristics, immunophenotype and prognosis in children with B cell type acute lymphoblastic leukemia (B-ALL) carrying different fusion genes.
  • Eighteen children were positive for TEL/AML1, 14 for E2A/PBX1, 11 for BCR/ABL,and 2 cases for MLL/AF4, and 35 cases were negative for all of the 4 fusion genes.
  • FAB-L2 morphology was commonly observed, but t(12;21) was often absence in these children.
  • Thirteen children showed FAB-L1 morphology.
  • In the 11 children with BCR/ABL+B-ALL, 10 children showed common B type immunophenotype.
  • FAB-L1 and FAB-L2 morphology was found in 4 children respectively.
  • Two children with MLL/AF4 positive B-ALL had high tumor load.
  • Their morphologic diagnosis was FAB-L1.
  • One child discontinued treatment at the early stage of chemotherapy, and the other child survived disease-free until now.
  • [MeSH-major] Gene Fusion. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Female. Homeodomain Proteins / genetics. Humans. Immunophenotyping. Infant. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350423.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; 146150-85-8 / E2A-Pbx1 fusion protein; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


6. Hafiz MG, Islam A, Siddique R: Back pain and vertebral compression: an unusual presentation of childhood acute lymphoblastic leukemia. Mymensingh Med J; 2010 Jan;19(1):130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Back pain and vertebral compression: an unusual presentation of childhood acute lymphoblastic leukemia.
  • Two weeks before admission, the hematological findings were suggestive of leukemia of lymphoblastic type.
  • Bone marrow morphology study and the cytochemistry of the aspirated marrow were consistent with acute lymphoblastic leukemia (ALL-L2).
  • Then, he was started protocol based chemotherapy for induction of remission, consolidation, high dose methotrexate and maintenance therapy.
  • Following six month of chemotherapy the boy was found with significant improvement of his physical, hematological and radiological abnormalities.


7. Laatiri MA, Chehata S, Amouri A, Sendi HS, Saad A, Ennabli S: [Acute lymphoblastic leukemia with Philadelphia chromosome: eight case reports]. Tunis Med; 2001 Jan;79(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia with Philadelphia chromosome: eight case reports].
  • [Transliterated title] Leucémie aiguë lymphoblastique avec chromosome Philadelphie: à propos de huit observations.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is an aggressive form of acute leukemia that children ALL.
  • Between 1991 and 1998, eight cases Ph+ ALL (7 males and one female) were diagnosed in our institution by successful cytogenetic studies.
  • According to the French-American-British (FAB) criteria, six patients were classified L1 and two L2.
  • The Ph+ as sole anomaly was seen in 2 patients (25%), while additional chromosome changes were observed in 6 cases.
  • The 2-year survival rae was 25% confirming the worse prognosis of this leukemia when treated with standard chemotherapy.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cytogenetics. Female. Follow-Up Studies. Humans. Infant. Karyotyping. Leukocyte Count. Male. Middle Aged. Prognosis. Remission Induction / methods. Survival Analysis. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332342.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


8. Mori A, Toyoshima N, Saito M, Oka T, Irie T, Morioka M: [Hypercalcemia and multiple osteolytic lesions associated with proinflammatory cytokines in a patient with acute lymphoblastic leukemia]. Rinsho Ketsueki; 2007 Jul;48(7):559-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypercalcemia and multiple osteolytic lesions associated with proinflammatory cytokines in a patient with acute lymphoblastic leukemia].
  • Bone marrow aspiration revealed increased lymphoblasts (48%), and the patient was diagnosed as having acute lymphoblastic leukemia (ALL, L2).
  • The bone marrow lymphoblast count decreased following combination chemotherapy, and a tendency towards improvement of the left ankle pain was also noted.
  • However, he died of acute pneumonia and gastrointestinal bleeding.
  • [MeSH-major] Cytokines / physiology. Hypercalcemia / etiology. Osteolysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695305.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Parathyroid Hormone-Related Protein; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


9. Du J, Hou S, Zhong C, Lai Z, Yang H, Dai J, Zhang D, Wang H, Guo Y, Ding J: Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis. J Mol Biol; 2008 Oct 17;382(4):835-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis.
  • Antibodies targeting osteopontin have shown promising therapeutic benefits against this disease.
  • We have previously reported a novel anti-RA monoclonal antibody, namely, 23C3, and shown it capable of alleviating the symptoms of RA in a murine collagen-induced arthritis model, restoring the cytokine production profile in joint tissues, and reducing T-cell recall responses to collagen type II.
  • Besides the complementarity-determining region loops, the framework region L2 of 23C3 is also shown to interact with the epitope peptide, which is not common in the antibody-antigen interactions and thus could be exploited in the engineering of 23C3.
  • These results not only provide valuable information for further improvement of 23C3 such as chimerization or humanization for its therapeutic application, but also reveal the features of this specific epitope of osteopontin that may be useful for the development of new antibody drugs against RA.
  • [MeSH-major] Antibodies, Monoclonal / chemistry. Arthritis, Rheumatoid / immunology. Immunoglobulin Fab Fragments / chemistry. Osteopontin / chemistry. Protein Structure, Secondary. Protein Structure, Tertiary
  • [MeSH-minor] Amino Acid Sequence. Animals. Arthritis, Experimental / drug therapy. Arthritis, Experimental / immunology. Crystallography, X-Ray. Epitopes. Humans. Mice. Models, Molecular. Molecular Sequence Data. Peptides / chemistry. Peptides / genetics. Peptides / metabolism. Protein Binding. Protein Folding

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36328-34 [10593924.001]
  • [Cites] Arthritis Rheum. 2008 Jul;58(7):2041-52 [18576331.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):342-51 [10896785.001]
  • [Cites] Arthritis Rheum. 2000 Jul;43(7):1597-605 [10902765.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1594-602 [11096166.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1055-61 [11342566.001]
  • [Cites] Rheum Dis Clin North Am. 2001 May;27(2):405-14, x [11396100.001]
  • [Cites] FEBS Lett. 2001 Aug 10;503(1):75-9 [11513858.001]
  • [Cites] Ageing Res Rev. 2002 Feb;1(1):135-47 [12039453.001]
  • [Cites] Arthritis Rheum. 2002 Jun;46(6):1443-50 [12115173.001]
  • [Cites] J Clin Invest. 2003 Jul;112(2):181-8 [12865407.001]
  • [Cites] J Cell Physiol. 2004 Jan;198(1):155-67 [14584055.001]
  • [Cites] Immunity. 2004 Oct;21(4):539-50 [15485631.001]
  • [Cites] J Exp Med. 1988 Sep 1;168(3):1099-109 [2459288.001]
  • [Cites] Science. 1990 May 11;248(4956):712-9 [2333521.001]
  • [Cites] Ciba Found Symp. 1991;159:13-28; discussion 28-39 [1959445.001]
  • [Cites] J Biol Chem. 1993 May 5;268(13):9901-7 [8486670.001]
  • [Cites] Proteins. 1993 May;16(1):1-7 [8497480.001]
  • [Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]
  • [Cites] J Mol Biol. 1993 Dec 20;234(4):946-50 [8263940.001]
  • [Cites] Curr Opin Struct Biol. 1994 Dec;4(6):857-67 [7536111.001]
  • [Cites] Curr Opin Struct Biol. 1995 Feb;5(1):103-13 [7773739.001]
  • [Cites] Br Med Bull. 1995 Apr;51(2):332-45 [7552067.001]
  • [Cites] J Biol Chem. 1995 Nov 3;270(44):26232-8 [7592829.001]
  • [Cites] Arthritis Rheum. 1996 Jul;39(7):1092-101 [8670316.001]
  • [Cites] J Mol Biol. 1997 Nov 7;273(4):927-48 [9367782.001]
  • [Cites] Mol Biol Cell. 1998 Jun;9(6):1425-35 [9614184.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):219-26 [9892210.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1060-7 [15761492.001]
  • [Cites] J Mol Biol. 2006 Apr 14;357(5):1566-74 [16497332.001]
  • [Cites] J Mol Biol. 2007 Feb 2;365(5):1533-44 [17125793.001]
  • [Cites] Nat Med. 2007 May;13(5):570-8 [17435770.001]
  • [Cites] J Leukoc Biol. 2007 Jun;81(6):1504-11 [17369493.001]
  • [Cites] Int Immunopharmacol. 2007 Nov;7(11):1460-70 [17761350.001]
  • [Cites] J Mol Biol. 2008 Jan 25;375(4):969-78 [18068724.001]
  • [Cites] Science. 2000 Feb 4;287(5454):860-4 [10657301.001]
  • (PMID = 18694758.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 3CXD/ 3DSF
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 23C3 monoclonal antibody; 0 / Antibodies, Monoclonal; 0 / Epitopes; 0 / Immunoglobulin Fab Fragments; 0 / Peptides; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2793339
  •  go-up   go-down


10. Jeon IS, Yi DY: Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus. Pediatr Hematol Oncol; 2009 Mar;26(2):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus.
  • Acute lymphoblastic leukemia (ALL), a primary hematologic malignancy that is especially common in childhood, occurs relatively rarely as a secondary malignant neoplasm.
  • Available data indicate that ALL often follows chemoradiotherapy for soft tissue sarcoma.
  • Perivascular epithelioid tumor (PEComa), a primitive mesenchymal tissue origin, can be classified as a soft tissue sarcoma.
  • An 11-year-old girl was diagnosed with ALL secondary to chemoradiotherapy (vincristine, ifosfamide, and anthracycline) and radiotherapy comprising 45 Gy to the whole pelvis for PEComa.
  • ALL, FAB L2, and immunophenotypically pro-B developed 16 months after the final chemotherapy treatment.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Perivascular Epithelioid Cell Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Uterine Neoplasms / complications
  • [MeSH-minor] Anthracyclines / adverse effects. Child. Cytogenetic Analysis. Female. Humans. Precursor Cells, B-Lymphoid / pathology. Topoisomerase II Inhibitors. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322738.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Topoisomerase II Inhibitors
  •  go-up   go-down


11. Laatiri MA, Chehata S, Amouri A, Bouaouina N, Gayed C, Saad A, Ennabli S: [Acute lymphoblastic leukemia in adults. Apropos of 42 cases]. Tunis Med; 2000 Feb;78(2):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia in adults. Apropos of 42 cases].
  • [Transliterated title] Leucémie aiguë lymphoblastique de l'adulte. A propos de 42 cas.
  • Between 1989 and 1995, 42 cases with acute lymphoblastic leukemia (18 males and 24 females) were diagnosed in our institution.
  • According to the French-American-British (FAB) criteria, 67% were classified L1 and 33% L2.
  • The 4-year survival rate was 28% confirming the worse prognosis of this leukemia when treated with standard chemotherapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Female. Humans. Leukocyte Count. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Tunisia / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10894047.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] TUNISIA
  •  go-up   go-down


12. Kode J, Dudhal N, Banavali S, Advani S, Chiplunkar S: Clonal T-cell receptor gamma and delta gene rearrangements in T-cell acute lymphoblastic leukemia at diagnosis: predictor of prognosis and response to chemotherapy. Leuk Lymphoma; 2004 Jan;45(1):125-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal T-cell receptor gamma and delta gene rearrangements in T-cell acute lymphoblastic leukemia at diagnosis: predictor of prognosis and response to chemotherapy.
  • Risk-based treatment assignment requires the availability of prognostic factors that reliably predict clinical outcome.
  • We studied peripheral blood samples of 50 newly diagnosed patients with T-ALL in India for incidence of clonal TCR gamma and delta junctional region gene rearrangements by PCR-coupled heteroduplex analysis.
  • A statistically significant association of L2 and L1 FAB blast morphology with TCRgammadelta + T-ALL and TCRalphabeta + T-ALL, respectively was observed (P = 0.001 by Fisher's Exact Test).
  • Thus we have identified clonal TCR gamma and delta junctional gene rearrangement status of T-ALL patients at diagnosis as a prognostic marker and predictor of response to chemotherapy.
  • In future, this may help in designing tailored and risk-adjusted (less aggressive and less toxic) therapies for subset of T-ALL patients.
  • [MeSH-major] Clone Cells / metabolism. Gene Rearrangement, T-Lymphocyte / genetics. Genes, T-Cell Receptor delta / genetics. Genes, T-Cell Receptor gamma / genetics. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Female. Genotype. Humans. Immunophenotyping. Male. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15061208.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Imberti D, Vallisa D, Anselmi E, Moroni CF, Bertè R, Lazzaro A, Bernuzzi P, Arcari AL, Cavanna L: Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia. Tumori; 2004 Jul-Aug;90(4):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia.
  • BACKGROUND: Venous thromboembolism (VTE) is a quite common complication in acute leukemia, although its real incidence is unknown.
  • The best treatment of this complication is still a matter of debate due to the very high risk of hemorrhage in this group of patients.
  • PATIENTS AND METHODS: From December 2000 to December 2002 four Caucasian patients with acute leukemia developed VTE complications.
  • Two patients with acute lymphoid leukemia (L1 and L2 according to the FAB classification) developed deep venous thrombosis during the administration of chemotherapy; one patient with acute myeloid leukemia (AML, M2 according to the FAB classification) had pulmonary thromboembolism at diagnosis, while another AML patient (M4 according to FAB) showed deep venous thrombosis as the first symptom of leukemia.
  • RESULTS: During antithrombotic treatment neither VTE recurrences nor hemorrhagic complications or heparin-induced thrombocytopenia occurred.
  • The platelet count at the beginning of enoxaparin treatment was very low (mean, 55,750 x 109/L; range, 12,000-121,000 x 10(9)/L) and treatment did not affect platelet recovery.
  • CONCLUSIONS: Enoxaparin proved to be efficacious and safe in the management of deep venous thrombosis with or without pulmonary embolism in patients affected by acute leukemia.
  • Enoxaparin cured acute venous thrombosis, prevented recurrences and did not cause any hemorrhagic complications despite prolonged severe thrombocytopenia.
  • [MeSH-major] Anticoagulants / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Enoxaparin / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thromboembolism / drug therapy. Venous Thrombosis / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Fibrinolytic Agents / therapeutic use. Hemorrhage / chemically induced. Humans. Male. Middle Aged. Platelet Count. Retrospective Studies. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510981.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Enoxaparin; 0 / Fibrinolytic Agents
  •  go-up   go-down


14. Liu Z, Liu XL, Du QF, Xu N, Zhong M, Song LL, Yi ZS, Liu QF, Meng FY, Zhou SY: [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):512-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
  • OBJECTIVE: To study the clinical characteristics and outcomes of BCR/ABL-positive acute lymphoblastic leukemia (BCR/ABL360888725-ALL) and screen the prognostic factors for BCR/ABL360888725-ALL.
  • METHODS: From January 2001 to May 2008, 59 patients (median age of 32 years ranging from 3 to 69 years) with the diagnosis of BCR/ABL360888725-ALL by fluorescence in situ hybridization received induction chemotherapy with VDLP-/+Ara-C regimen.
  • The patients who failed to respond to the chemotherapy received subsequent consolidation chemotherapy with imatinib (400-800 mg/day) (17 cases) or allogeneic hematopoietic stem cell transplantation (allo-HSCT) (16 cases).
  • According to the FAB classification, 56 cases were divided into L1, L2 and biphenotypic acute leukemia (BAL) subgroups, and their CR rates were 66.7% (6/9), 63.2% (24/38) and 22.2% (2/9) (P=0.029), with OSs of 2-yrs of 22.2%, 27.0% and 22.0%, respectively (P=0.623).
  • In terms of immunophenotype grouping by EGIL, the patients with ALL, myeloid antigen-positive ALL and BAL had CR rates of 61.1% (11/18), 60.6% (20/33) and 12.5% (1/8) (P=0.039), and the OSs of 2-yrs of 22.7%, 21.0% and 18.8%, respectively (P=0.643).
  • In 55 patients with known karyotype, the CR rates were 71.4%(5/7), 70.8% (17/24) and 37.5% (9/24) in normal, sole t(9;22) abnormality, t(9;22) with additional abnormalities groups (P=0.046), with the OSs of 2-yrs of 42.9%, 34.0% and 7.3%, respectively (P=0.000).
  • The OSs of 2-yrs were significantly higher in patients with consolidation chemotherapy with imatinib than those without (48.0% vs 11.2%, P=0.001), and allo-HSCT was associated with significantly higher OSs of 2-yrs than exclusive chemotherapy (54.2% and 8.5%, P=0.000).
  • CONCLUSION: BCR/ABL360888725-ALL with WBC> or =100 x 10(9)/L, presence of BAL diagnosed by FAB or FACM, t(9;22) with additional chromosome abnormalities all adversely affect the treatment results, and additional chromosome abnormalities and septicemia are associated with lower OSs of 2-yrs.
  • Imatinib treatment and allo-HSCT can both improve the OSs of 2-yrs of the patients with BCR/ABL(+)-ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genes, abl / genetics. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304540.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


15. Colović M, Bogdanović A, Janković G, Kraguljac N, Suvajdzić N: Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol. Chemotherapy; 2003 Jun;49(3):138-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol.
  • BACKGROUND: Between January 1989 and July 1995, a prospective study of the therapeutic efficacy of the LALA 87 protocol in adult acute lymphoblastic leukaemia (ALL) has been conducted.
  • The median age of the patients was 40 years (range: 15-65), the gender ratio (M/F) was 66/46, and the morphologic FAB (French-American-British) profile was L1 in 30 (26.9%) patients, L2 in 71 (63.3%) and L3 morphology in 11 (9.8%) of the patients.
  • Maintenance therapy was given for 2 years and consisted of different drugs as reinforcement, daily 6-mercaptopurine and weekly methotrexate.
  • Among the relapsed patients, 9 developed CNS disease in spite of CNS prophylaxis during induction chemotherapy.
  • CONCLUSION: The results support the strategy of applying more effort and other treatment modalities in the therapy of ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Administration, Oral. Adolescent. Adult. Age Factors. Aged. Central Nervous System Neoplasms / prevention & control. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12815207.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down






Advertisement